Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Norris Medicines held its 34th Annual General Meeting on 29th September 2025 through video conferencing. Eight resolutions were put to vote via remote e-voting and e-voting during the AGM, and all were passed with overwhelming majority — 99.58% in favour (65,95,220 votes) and only 0.42% against (27,660 votes), with no invalid votes. Ordinary resolutions included adoption of audited financials for FY ended March 2025, re-appointment of Mr. Praveen I. Bafna as director, appointment of Ms. Sathya Venkatachalam as Independent Director, and appointment of HSPN & Associates LLP as Secretarial Auditor. Special resolutions approved revision in managerial remuneration of Executive Director Mr. Vimal D. Shah, increase in borrowing limits, authorization to sell or dispose of the company's undertaking, and enhancement of limits under Section 186 of the Companies Act for loans/investments.
All routine and governance resolutions were passed with near-unanimous shareholder support, indicating no significant dissent. The increased borrowing limits and Section 186 powers give the company greater flexibility to raise funds and make investments, while revised remuneration for the Executive Director has been shareholder-approved.